정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 415 | Recruiting | Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older | COVID-19 (Healthy Volunteers) | Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1 Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2 Biological: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3 Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, Dosage A Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, Dosage A Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, Dosage B Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, Dosage B Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1 Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2 Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3 Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4 |
Phase 3 | Sanofi Pasteur, a Sanofi Company, GlaxoSmithKline | INDUSTRY | 5414 | All | 18 Years | Investigational Site Number :8400270, Birmingham, Alabama, United States Investigational Site Number :8400251, Chandler, Arizona, United States Investigational Site Number :8400271, Glendale, Arizona, United States Investigational Site Number :8400220, Los Angeles, California, United States Investigational Site Number :8400094, Rolling Hills Estates, California, United States Investigational Site Number :8400173, San Diego, California, United States Investigational Site Number :8400239, New Haven, Connecticut, United States Investigational Site Number :8400212, Washington, District of Columbia, United States Investigational Site Number :8400089, Hollywood, Florida, United States Investigational Site Number :8400057, Melbourne, Florida, United States Investigational Site Number :8400179, Orlando, Florida, United States Investigational Site Number :8400201, Decatur, Georgia, United States Investigational Site Number :8400269, Chicago, Illinois, United States Investigational Site Number :8400187, Peoria, Illinois, United States Investigational Site Number :8400272, Evansville, Indiana, United States Investigational Site Number :8400045, New Orleans, Louisiana, United States Investigational Site Number :8400048, Rockville, Maryland, United States Investigational Site Number :8400199, Boston, Massachusetts, United States Investigational Site Number :8400100, Saint Louis, Missouri, United States Investigational Site Number :8400030, Omaha, Nebraska, United States Investigational Site Number :8400072, Teaneck, New Jersey, United States Investigational Site Number :8400267, Brooklyn, New York, United States Investigational Site Number :8400230, New York, New York, United States Investigational Site Number :8400203, New York, New York, United States Investigational Site Number :8400207, Rochester, New York, United States Investigational Site Number :8400233, Pittsburgh, Pennsylvania, United States Investigational Site Number :8400097, North Charleston, South Carolina, United States Investigational Site Number :8400204, Rapid City, South Dakota, United States Investigational Site Number :8400191, Austin, Texas, United States Investigational Site Number :0360001, South Brisbane, Queensland, Australia Investigational Site Number :0360003, Norwood, Australia Investigational Site Number :0360002, Southport, Australia Investigational Site Number :0360004, Woodville, Australia Investigational Site Number :2500013, Dijon, France Investigational Site Number :2500008, Limoges, France Investigational Site Number :2500014, Lyon, France Investigational Site Number :2500015, Marseille, France Investigational Site Number :2500016, Marseille, France Investigational Site Number :2500006, Nantes, France Investigational Site Number :2500005, Paris, France Investigational Site Number :2500003, Pessac, France Investigational Site Number :2500007, Pierre Benite, France Investigational Site Number :2500004, Rennes, France Investigational Site Number :2500002, Tours Cedex 1, France Investigational Site Number :3400002, Municipio Del Distrito Central, Honduras Investigational Site Number :3400001, San Pedro Sula, Honduras Investigational Site Number :4040006, Kericho, Kenya Investigational Site Number :7240009, Madrid, Spain Investigational Site Number :8260010, Harrow, United Kingdom Investigational Site Number :8260015, London, United Kingdom Investigational Site Number :8260012, Southampton, United Kingdom |
| 414 | Recruiting | Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. | Coronavirus Infection | Drug: Ruxolitinib plus simvastatin Other: Standard of Care |
Phase 2 | Fundacion de investigacion HM, Apices Soluciones S.L. | OTHER | 94 | All | 18 Years | Hospital Universitario Madrid Sanchinarro, Madrid, Spain |
| 413 | Completed | Study of Sargramostim in Patients With COVID-19 | Sars-CoV2 | Drug: Sargramostim Drug: Standard of care |
Phase 2 | Partner Therapeutics, Inc., United States Department of Defense | INDUSTRY | 122 | All | 18 Years | St. Jude Medical Center, Fullerton, California, United States St. Joseph Hospital of Orange, Orange, California, United States California Pacific Medical Center - Van Ness Campus, San Francisco, California, United States TidalHealth Peninsula Regional, Inc, Salisbury, Maryland, United States University of Missouri Health Care, Columbia, Missouri, United States Great Plains Health, North Platte, Nebraska, United States Richmond University Medical Center, Staten Island, New York, United States Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States University of Toledo Medical Center, Toledo, Ohio, United States Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States University of Utah Health, Salt Lake City, Utah, United States |
| 412 | Recruiting | Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP | SARS-CoV2 | Biological: Serology SARS-CoV2 Behavioral: Data collection |
Not Applicable | Assistance Publique - Hopitaux de Paris | OTHER | 400 | All | Centre d'investigation clinique (CIC) Necker Cochin in Necker Children's Hospital, Paris, France | |
| 411 | Completed | Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19 | Sars-CoV2 | Drug: Octagam | Phase 4 | George Sakoulas, MD, Octapharma | OTHER | 34 | All | 18 Years | Sharp Grossmont Hospital, La Mesa, California, United States Sharp Memorial Hospital, San Diego, California, United States |
| 410 | Withdrawn | Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19 | Covid19 | Drug: TB006 Other: Placebo |
Phase 1 | TrueBinding, Inc. | INDUSTRY | 0 | All | 18 Years | |
| 409 | Completed | Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults | Covid19 | Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly |
Phase 3 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 1040 | All | 18 Years | Dafeng District Center for Disease Prevention and Control, Yancheng, Jiangsu, China |
